Skip to Main Content

Author Details

Yin Liu
Fudan University Shanghai Cancer Center
2011
28
14
PMIDPaper TitleJournal TitlePublished Year
36426808Nab-paclitaxel Followed by Dose-dense Epirubicin/Cyclophosphamide in Neoadjuvant Chemotherapy for Triple-negative Breast Cancer: A Phase II Study.Oncologist2023
36973538Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trial.Cell Res2023
37201522CCL19<sup>+</sup> dendritic cells potentiate clinical benefit of anti-PD-(L)1 immunotherapy in triple-negative breast cancer.Med2023
35767614In vivo multidimensional CRISPR screens identify <i>Lgals2</i> as an immunotherapy target in triple-negative breast cancer.Sci Adv2022
35613826Ccl3 enhances docetaxel chemosensitivity in breast cancer by triggering proinflammatory macrophage polarization.J Immunother Cancer2022
32975708Randomized phase II clinical trial and biomarker analysis of paclitaxel plus epirubicin versus vinorelbine plus epirubicin as neoadjuvant chemotherapy in locally advanced HER2-negative breast cancer with TEKT4 variations.Breast Cancer Res Treat2021
33898305Tumor Size Still Impacts Prognosis in Breast Cancer With Extensive Nodal Involvement.Front Oncol2021
34868273A Combined Nomogram Model to Predict Disease-free Survival in Triple-Negative Breast Cancer Patients With Neoadjuvant Chemotherapy.Front Genet2021
33968682Serum HER2 levels predict treatment efficacy and prognosis in patients with HER2-positive breast cancer undergoing neoadjuvant treatment.Gland Surg2021
33420488Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression.Nat Cell Biol2021
32719455Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial.Cell Res2021
32272493The Predictive Value of Early Changes in <sup>18</sup> F-Fluoroestradiol Positron Emission Tomography/Computed Tomography During Fulvestrant 500 mg Therapy in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer.Oncologist2020
32413516CRISPR Screens Identify Essential Cell Growth Mediators in BRAF Inhibitor-resistant Melanoma.Genomics Proteomics Bioinformatics2020
30052635CCL20 triggered by chemotherapy hinders the therapeutic efficacy of breast cancer.PLoS Biol2018
27925176PD-L1 expression of the residual tumor serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy.Int J Cancer2017
28289232Transcriptional landscape of the human cell cycle.Proc Natl Acad Sci U S A2017
26916442An Integrative Pharmacogenomic Approach Identifies Two-drug Combination Therapies for Personalized Cancer Medicine.Sci Rep2016
25012266Clinical and pathological response to neoadjuvant chemotherapy based on primary tumor reduction is correlated to survival in hormone receptor-positive but not hormone receptor-negative locally advanced breast cancer.Ann Surg Oncol2015
26220863Towards pathway-centric cancer therapies via pharmacogenomic profiling analysis of ERK signalling pathway.Clin Transl Med2015
26107623Overweight as a Prognostic Factor for Triple-Negative Breast Cancers in Chinese Women.PLoS One2015
25884806Association between CHEK2 H371Y mutation and response to neoadjuvant chemotherapy in women with breast cancer.BMC Cancer2015
24013900Lymph node counts and ratio in axillary dissections following neoadjuvant chemotherapy for breast cancer: a better alternative to traditional pN staging.Ann Surg Oncol2014
25188383Similar prognoses for invasive micropapillary breast carcinoma and pure invasive ductal carcinoma: a retrospectively matched cohort study in China.PLoS One2014
24317252Refined DNase-seq protocol and data analysis reveals intrinsic bias in transcription factor footprint identification.Nat Methods2014
24141623The residual tumor autophagy marker LC3B serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy.Clin Cancer Res2013
24289519Prognostic and predictive value of Phospho-p44/42 and pAKT in HER2-positive locally advanced breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy.World J Surg Oncol2013
24340082A prognostic model for triple-negative breast cancer patients based on node status, cathepsin-D and Ki-67 index.PLoS One2013
21618645A recurrent CHEK2 p.H371Y mutation is associated with breast cancer risk in Chinese women.Hum Mutat2011
  • 1 - 28 of 28

Recommended Authors

Chiara Corti
University of Milano
Career Start Year 2017
Number of shared co-authors 0
Kevin Punie
Leuven Cancer Institute and University Hospitals Leuven
Career Start Year 2015
Number of shared co-authors 0
Martin Sj??str??m
University of California-San Francisco
Career Start Year 2013
Number of shared co-authors 4
Konstantinos Tryfonidis
Merck & Co., Inc.
Career Start Year 2011
Number of shared co-authors 0
Carmen Criscitiello
University of Milano
Career Start Year 2008
Number of shared co-authors 0
Gabriele Zoppoli
University of Genoa and Ospedale Policlinico San Martino
Career Start Year 2008
Number of shared co-authors 0
Bora Lim
The University of Texas MD Anderson Cancer Center
Career Start Year 2007
Number of shared co-authors 1
Hannah Y Wen
Memorial Sloan Kettering Cancer Center
Career Start Year 2007
Number of shared co-authors 1
Naoto Kondo
Nagoya City University Graduate School of Medical Sciences
Career Start Year 2006
Number of shared co-authors 0
Catherine M Kelly
Mater Misericordiae University Hospital
Career Start Year 2006
Number of shared co-authors 0
Christina Yau
University of California San Francisco
Career Start Year 2005
Number of shared co-authors 0
Sara M Tolaney
Dana-Farber Cancer Institute
Career Start Year 2005
Number of shared co-authors 0
Jeong Eon Lee
Samsung Medical Center, Sungkyunkwan University School of Medicine
Career Start Year 2004
Number of shared co-authors 0
Aditya Bardia
Massachusetts General Hospital Cancer Center
Career Start Year 2004
Number of shared co-authors 0
David W Cescon
Princess Margaret Cancer Centre
Career Start Year 2003
Number of shared co-authors 3
Philippe L Bedard
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2002
Number of shared co-authors 3
Peter A Fasching
Otto-Friedrich-University Bamberg
Career Start Year 2002
Number of shared co-authors 0
Nicola Fusco
IEO European Institute of Oncology IRCCS
Career Start Year 2002
Number of shared co-authors 1
Wei Zhang
Children's Hospital, Zhejiang University School of Medicine
Career Start Year 2001
Number of shared co-authors 0
Richard B Schwab
Department of Medicine and Moores Cancer Center, University of California San Diego
Career Start Year 2000
Number of shared co-authors 0
Fatima Cardoso
Champalimaud Clinical Center/Champalimaud Foundation
Career Start Year 2000
Number of shared co-authors 0
Ingrid A Mayer
Vanderbilt University Medical Center
Career Start Year 2000
Number of shared co-authors 0
Massimo Cristofanilli
Weill Cornell School of Medicine
Career Start Year 1998
Number of shared co-authors 0
Ingrid Hedenfalk
Lund University and Skane University Hospital
Career Start Year 1997
Number of shared co-authors 0
Giuseppe Curigliano
University of Milan
Career Start Year 1996
Number of shared co-authors 0
Steven J Isakoff
Massachusetts General Hospital
Career Start Year 1995
Number of shared co-authors 0
Naoto T Ueno
Cancer Research Center of Hawaii: University of Hawai'i Cancer Center.
Career Start Year 1995
Number of shared co-authors 0
Funda Meric-Bernstam
University of Texas MD Anderson Cancer Center
Career Start Year 1990
Number of shared co-authors 1
John W M Martens
Erasmus Medical Center (MC) Cancer Institute
Career Start Year 1989
Number of shared co-authors 1
Laura J Van't Veer
University of California San Francisco
Career Start Year 1984
Number of shared co-authors 0

Collaborators

Myles Brown
Co-authored papers 4
Xiaole Shirley Liu
Co-authored papers 4
Housheng Hansen He
Princess Margaret Cancer Center, University Health Network, University of Toronto
Co-authored papers 3
Fei Teng
Ningbo First Hospital
Co-authored papers 3
Clifford A Meyer
Co-authored papers 2
Sujun Chen
Princess Margaret Cancer Center/University Health Network
Co-authored papers 2
Fraser Soares
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 2
Chao Wang
Novel Bioinformatics Co.
Co-authored papers 1
Michael Fraser
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 1
Yasheng Zhu
Changhai Hospital, Naval Military Medical University
Co-authored papers 1
Song Wu
The Third Affiliated Hospital of Shenzhen University (Luohu Hospital Group)
Co-authored papers 1
Fan Zhang
Huaihe Hospital of Henan University
Co-authored papers 1
Na Zhang
Obstetrics and Gynecology Hospital of Fudan University
Co-authored papers 1
Fubo Wang
Center for Genomic and Personalized Medicine, Guangxi Medical University
Co-authored papers 1
Fei Liu
Shanghai Changhai Hospital
Co-authored papers 1
Bo Zhang
Novel Bioinformatics Co.
Co-authored papers 1
Weidong Chen
Novel Bioinformatics Co.
Co-authored papers 1
Dai Chen
University of Washington
Co-authored papers 1
Jianhua Wang
Anhui University of Science & Technology
Co-authored papers 1
Zhengfang Yi
The Institute of Biomedical Sciences, East China Normal University
Co-authored papers 1
Helen Loo Yau
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 1
Peng Jiang
Anhui Medical University
Co-authored papers 1
Paul C Boutros
University of California los angeles
Co-authored papers 1
Qinghua Guo
Novel Bioinformatics Co.
Co-authored papers 1
Zhou Jiang
China University of Geosciences
Co-authored papers 1
Alejandro Berlin
University of Toronto, Princess Margaret Cancer Centre
Co-authored papers 1
Daniel D De Carvalho
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 1
Theodorus H van der Kwast
University Health Network, University of Toronto
Co-authored papers 1
Keqin Dong
Shanghai Changhai Hospital
Co-authored papers 1
Shengen Shawn Hu
Co-authored papers 1
Release 1.2